I Treat Cholesterol Differently Now: Statins, PCSK9s, Ezetimibe & Gene Editing
In a Nutshell
The core message is that aggressive LDL/apoB lowering has no floor and delivers exponential cardiovascular benefit when started early and sustained lifelong. Most patients can reach very low targets with cheap, generic combinations—high-intensity statin plus ezetimibe—and those who are statin-intolerant or still short of goal now have well-tolerated, once- or twice-yearly injectables (PCSK9 antibodies, inclisiran, bempedoic acid) that cut LDL another 50 % or more. Emerging one-time gene-editing therapies (Verve-101) and multiple Lp(a)-specific agents in late-stage trials promise permanent or near-permanent solutions within the next decade.
These notes were generated by AI and may contain inaccuracies.
One infusion and your cholesterol drops 60% permanently. The gene causing the problem gets edited and you never need a statin or injection ever again. This is real and it's in trials right now, fully enrolled with phase one data published and peer-reviewed. And if the safety holds, some of you watching this could be in the first generation of people who could say, "I fixed my cholesterol once and done."
If you've been diagnosed with high cholesterol or atherosclerosis or you just had a cardiac event or if you are like so many of us who have watched our parents and grandparents battle this disease, you deserve to know what the ceiling of what's possible actually looks like. My grandfather died of a stroke. My grandmother died of sudden cardiac arrest. My aunt died of aortic dissection and my father, while I'm recording this, is still recovering from a heart transplant. All on my paternal side. When my own Ava became back at 128, I was scared. I'm a Stanford-trained physician and I've been practicing for over a decade. I know exactly how to read the data and what matters and what doesn't. I still had a moment where I sat with that result and thought, "Okay, now it's my turn."
So, here is what I did and everything I considered and what you should know about your options from a $4 generic that has more clinical evidence behind it than almost any drug developed to a twice-a-year injection most patients have never heard of to a gene-editing therapy very close to reality. Quick orientation, this is part three of the modern lipid playbook. In part one, we covered the disease. Part two was how to test properly. Links are in the description. Each video stands alone. Now, this video, part three, is for you if you've just gotten a statin prescription and you went home and spent three hours reading terrifying things on the internet. This is for you if you've tried one and stopped because of muscle pain. And this is especially for you if you're doing everything right but your lipids are still high because for many of us, this is not a lifestyle failure. It's genetics. And that change everything about what drugs you need.
Before I walk you through every drug, you need to understand one foundational idea that most patients never get explained to them in the office. How low should your cholesterol actually go? For most of your life and probably for most of what your doctor has told you, the answer has been until it's in the normal range. Hit that target, move on. An LDL under 100 is considered optimal in most primary care offices. Under 70 if you have a high-risk condition. Most doctors just check your LDLC and call it a day. The data tells a very different story. In fact, data suggests there is no floor.
The IMPROVE-IT trial enrolled patients who had already had a heart attack. Half got a statin alone, half got a statin plus a second drug. The combination group got their LDL down to about 54. The statin only drugs stayed around 70. That 16-point difference translated to fewer heart attacks, fewer strokes, fewer cardiovascular events over 7 years of follow-up. The people who went lower did better.
Then FOURIER, over 27,000 patients with established heart disease already on statins given an injectable drug. Their LDL dropped to a median of 30 and they had 15% fewer cardiovascular deaths. The open-label extension of FOURIER followed some of these patients for up to 8.6 years. Some had LDLs below 20. They kept doing better. There seemed to be no safety signal concern, no cognitive problems which a lot of people worry about, absolutely no cancer, just fewer heart attacks, fewer strokes, the lower the number went.
So, here's why this makes biological sense. Newborns have an LDL of about 30 to 40. People with naturally occurring genetic mutations that permanently lower their PCSK9 walk around with LDLs in the 20s their entire lives and they don't have any adverse effects. They just have dramatically lower rates of heart disease. That's the human proof of concept. So, the answer to how low it is, as always, you can safely and sustainably get it for as long as possible, starting as early as possible. Think of this like sun exposure, or even smoking exposure. Damage is cumulative. I call it cholesterol years, inspired by smoking years, which is how we gauge risk for smokers. A 35-year-old with an apoB of 130 is accumulating atherogenic exposure every single day for the next 30 years if they don't get intervention. By the time they're 65, that's decades of particles embedding in their artery walls, even if their 10-year risk calculator still says low risk. And sadly, that risk calculator is still being used in primary care offices everywhere.
The Mendelian randomization data shows that each decade of earlier LDL reduction compounds the benefit exponentially. Starting treatment at 40 instead of 60 doesn't just buy you 20 extra years of therapy. It prevents the plaque from forming in the first place. That is a fundamentally different outcome. This is why recently, finally, the 2026 ACC AHA guidelines now recommend starting the statin conversation at age 30. Not because every 30-year-old needs medication, but because the math changes entirely when you think in decades instead of years. If you're watching this in your 40s, 50s, or 60s with an already elevated apoB, the goal is to get it as low as safely possible and keep it there for as long as possible. There's no finish line when you've done enough. This is a long game.
Now, before I tell you which drugs work, I need to tell you something that too many doctors skip entirely. The reason your number is high changes everything about which drugs you need. Treating elevated cholesterol as if it's one condition with one cause is like treating a fever without asking what's bacterial or viral. The treatment is going to be different. And if your doctor has never asked you these questions, the conversation is incomplete. Three genetic scenarios matter enormously for treatment decisions.
LP(a) - Lipoprotein(a)
First, LP little A. Approximately 90% inherited, about 20 to 25% of the global population has an LP little A, and statins don't touch it. Ezetimibe doesn't touch it. You still need to treat your other lipid numbers aggressively, but the LP little A component requires its own approach. The drugs that do this are coming, and I'm going to cover them in the pipeline section, but they're not yet FDA approved. If your LP little A is elevated, knowing that changes your urgency, your targets, and how closely you should be watching.
Familial Hypercholesterolemia (FH)
Second, familial hypercholesterolemia or hyperlipidemia. This affects about 1 in 250 people, and 90% of them don't know they have it. If you have FH, your LDL receptor, the protein in your liver that normally grabs the LDL out of your blood, is genetically broken. You've probably had sky-high LDLs since birth. No amount of dietary restriction or exercise will fix a structural protein defect. People with FH often need injectable therapy regardless of lifestyle, often from a young age. If your LDL has been stubbornly high your entire adult life despite genuine effort, this is worth asking your doctor about testing.
Ancestry and Genetic Background
Third, ancestry matters so much more than physicians acknowledge. For example, South Asian ancestry carries significantly higher baseline coronary artery disease risk even with what appears to be a normal LDL level. Ashkenazi Jewish populations have higher rates of FH. East Asian and black patients may metabolize certain statins very differently due to variations in drug transport genes. I would know. This is not about stereotyping or profiling. This is about precision. Your genetic background is real data, and a physician who doesn't ask about it is leaving information on the table that can change your treatment plan. If your doctor prescribed a statin without ever checking your LP little A, without asking specifically about relatives who had heart attacks before age 65, without considering your ethnic background or testing your genomics. They skipped some important steps that would change what comes next.
We're going to go through this in a great deal of depth. Now, the drugs. Let's go through everyone. And trust me, this is really interesting. This is a field that has really blossomed in the last few years and the upcoming years are going to be astounding. Statins are one of the most studied drugs in the history of medicine and today it feels like it's one of the most controversial. The cholesterol treatment trialists meta-analysis involved over 170,000 patients across dozens of randomized controlled trials and showed a 22% reduction in major vascular events for every 1 mmol per liter reduction in LDL. Extraordinary, consistent, replicated evidence across different countries, different populations, different study designs. Statins work. That is not an ambiguous statement. But, I know why you're skeptical because the internet has done a number on statins. So, let me walk through every major concern.
Muscle pain or myalgias. This is the number one reason people stop statins and I take it very seriously because I experienced it myself. When I started myself on rosuvastatin, I started noticing that I had felt kind of achy as if I'd worked out at the gym too much. But, then it really got to me. Even woke me up in the middle of my sleep when my jaw started aching. My partner said that it was cuz I talked too much and that may have been part of the problem, but it turned out it was the statin. So, between 1 and 10% of statin users report muscle symptoms and that wide range reflects how you define symptom and how you ask the question. True statin myopathy, actual muscle damage with elevated enzymes, affects less than 0.1% of patients. Rhabdomyolysis, the catastrophic muscle breakdown you've read about where you urinate brown, is exceptionally rare. About 1 in 10,000 patient years. But, general muscle aches, heaviness, and soreness, that is pretty common and people feel it.
However, a significant portion of it is what researchers call the nocebo effect. You expect to get muscle pain because you read about it, and then you get muscle pain. That being said, it's just one option. If someone doesn't want to be on a statin because they feel like they have some muscle pain, then they don't have to be because we've got a lot of other options. The SAMSON trial is the most striking example I know of. Patients who believed they were statin intolerant were randomized in a blinded crossover design to a statin, a placebo, or nothing. 90% of the symptoms they attributed to the statin also occurred on the placebo. So, that's not me saying your muscle pain isn't real. It maybe is real. It was real in my case. I totally believe it. It was very unusual and not what I expected. It simply means that the cause may not be what you think it is, and before abandoning one of the most effective cardiovascular medications ever developed, it's worth a re-challenge with a different statin or a lower dose.
All right, let's make this even more actionable. There are genomic tests that can detect something called SLCO1B1 that predicts whether your muscles are particularly vulnerable to certain statins. About 15% of people carry a variant that meaningfully increases the risk of muscle symptoms, particularly with simvastatin. The fix is simple. You switch statins. Rosuvastatin, which is the one I tried, pravastatin, and fluvastatin are much less affected by this variant. So, if you were put on a simvastatin and you developed muscle aches, your problem might be one gene variant and one type of statin, not the entire class. We're going to go deep on genomics and lipids part four, so hang in there for more info there. That episode could literally save you years of unnecessary avoidance or the wrong medications.
I want to address a supplement, CoQ10. So, statins do lower circulating CoQ10, which is important for mitochondrial function. The theory is that this contributes to muscle symptoms. The clinical trial evidence for supplementation, however, is pretty mixed and no study has shown consistent benefit with supplementation. Some patients wear by anyways and I'm not going to argue with them because I often tell patients to go ahead and use CoQ10 in general for mitochondrial support. It's not a bad thing.
And then there is the CAC paradox. So, if you've had a coronary calcium score done and your number went up while on a statin, you might be alarmed. But, I'm here to tell you that you don't have to be because what statins do is stabilize plaque. That is a good thing. So, they'll convert the dangerous vulnerable soft plaque into harder calcified stable plaque. A CAC score, remember, they're just detecting calcified plaque. So, it might be lower and then it might get harder because more of that soft plaque got stabilized and turned into calcium. It means the drug is working and it's making the existing plaque safer.
Okay, let's talk diabetes risk. This is real and I won't wave it away. High-intensity statins carry a small measurable increase in the risk of developing type 2 diabetes. But, there's some context. For every case of diabetes attributable to statin therapy, multiple heart attacks and strokes are prevented. So, the net benefit still overwhelmingly favors treatment, especially in people already at cardiovascular risk. If you're at risk for diabetes, monitor your glucose and take the interventions for that. Don't avoid a life-saving cardiovascular medication because of this.
So, some people are worried about statins affecting memory and cognition. This doesn't seem to be supported by the large-scale trial data. The FDA added a label warning based on post-marketing reports, but in the long-term 4-year extension where patients had extremely low LDL for years, they had no neurocognitive signal whatsoever. So, the fear seems to be dramatically outsized relative to the evidence.
Now, let's talk about what statins to use. Two statins dominate modern prescribing, rosuvastatin and atorvastatin. Both are high-intensity, generic, and inexpensive. Rosuvastatin is slightly more potent milligram for milligram and is water soluble, which theoretically means less muscle penetration. Atorvastatin has decades of outcome data and a very long half-life. So, time of day doesn't matter. You might have heard take your statin at the nighttime, it doesn't matter for something like atorvastatin. Pravastatin is gentler and good for patients worried about tolerability. Simvastatin at 80 mg is essentially obsolete.
One pharmacogenomics note for rosuvastatin that almost nobody tells patients. ABCG2 is a transporter that helps clear rosuvastatin from your system. So, when you take the statin, it helps clean it up. It helps metabolize it. However, about 35 to 40% of East Asian, like myself, patients carry a variant called Q141K that transforms that transporter to be a little bit less effective. So, roughly twice the amount of drug ends up in your system compared to people without that variant. The FDA actually recognizes this and says it on the rosuvastatin label. It recommends as Asian patients start at 5 mg, not the standard 10 mg. So, remember I said I had muscle aches. When I looked up my SLCO1B1 gene, it was normal. So, no genetic reason I'd have more muscle aches on statins, right? Then I went looking for the gene for rosuvastatin intolerance and found it. I am heterozygous for ABCG2 Q141K, which is a mouthful, but basically means I was getting roughly 1 and 1/2 times the drug exposure of someone with a normal ABCG2 function. I wasn't taking 20 mg, but my body thought I was taking a 30 mg dose. My muscles weren't being extra dramatic, they were just responding to an effectively higher dose than what was on the label.
So, what does that mean practically? The good news is if you have these changes in your genome, then you don't need 40 mg to get very strong LDL lowering. You're already getting elevated drug exposure at lower amounts. And at higher doses, unfortunately, the adverse effects risk, including myopathy and liver enzyme elevations, goes up proportionally. If you have 23andMe, Ancestry, or any raw genotyping data, search for your genomes. You can take a look for them by typing in those letters in each of these databases.
Now, a quick note about why statins are so miraculous. Generic atorvastatin and rosuvastatin cost between $4.15 per month. That's one of the cheapest, most effective cardiovascular drugs we have. The fact that people avoid it out of fear, while spending $150 a month on supplements with no cardiovascular outcome data, is something I will never fully accept. That being said, everyone needs to make their own decisions. And if you're like me and you suffer from bad side effects with a statin, it's reasonable to turn to another option.
Now, ezetimibe. If you have not heard about this drug, that tells you almost everything you need to know about how it's been treated in clinical practice. It is cheap, extraordinarily well tolerated, and adds meaningful LDL reduction on top of any other drug, and most primary care physicians barely think about it. Probably because drug reps didn't come around knocking on our doors about it. So, here's how it works. Ezetimibe, or Zetia. Cholesterol first enters your bloodstream from two sources. Your liver makes it, and your gut also absorbs it from food and from bile your liver recycles. Statins block production in the liver. Ezetimibe blocks a protein in the lining of your small intestine that absorbs cholesterol coming in from the gut. So, if you use both of these drug classes, you get two pathways and completely additive effects. So, on top of a statin, ezetimibe reduces LDL another 15 to 25%, which is significant.
The IMPROVE-IT trial enrolled over 18,000 patients who'd had a heart attack. Statin alone versus statin plus ezetimibe followed for 7 years. The combo group's LDL was 54 compared to 70 in the statin only group. That 16-point difference led to a statistically significant reduction in cardiovascular events. That's real heart attacks and strokes prevented. What was the effect size, you might wonder? It was just about 2% absolute reduction, but take the no floor principle from earlier. Every point matters. A well-tolerated $15 pill that moves your number another 20% is not a footnote. It should be part of your protocol. Not to mention, the side effect profile is essentially nothing. You don't get muscle aches, you don't get liver effects. Some rare occasional mild GI symptoms in a very, very small portion of people, but most of those people will feel better after a while as well.
Of course, genetics is always at play as well. There's a gene that is ezetimibe targets, NPC1L1, and it has variants that change how well you absorb cholesterol from your gut in the first place, and how dramatically ezetimibe can block that absorption. About one in eight people carry a variant that produces a 35 to 36% LDL reduction from ezetimibe compared to a 24% in everyone else. Same exact drug, same dose, but a 52% greater response in some people. That's why some patients are going to see remarkable results, and others just some modest ones. For what it's worth, I checked my own NPC1L1 data. I don't have the variant, and my cholesterol absorption pathway is fully intact, which is part of why, probably, that I responded well to ezetimibe when I finally got on it.
All right, now let's talk about have a genuine statin intolerance and a little bit of extra cash, or really good insurance. If you've tried rosuvastatin, atorvastatin, pravastatin, and just nothing worked, and you still get muscle aches, you probably felt stuck. Bempedoic acid was developed specifically for you. This works in the same cholesterol production pathway as statins, but it hits a different enzyme called ACL, that's one step upstream from where statins act. It's the same exact road, highway, you can imagine, just different toll booths. And the key design feature is that bempedoic acid is a pro drug. So, it needs to be chemically activated by an enzyme called ACSVL1 to work. That enzyme exists in your liver and not in your skeletal muscle. So, the drug is physically incapable of causing muscle toxicity. It never is active in your muscles. The mechanism that caused your statin muscle pain simply is impossible with bempedoic acid.
The key question, does it prevent heart attacks? The CLEAR outcomes trial answered that directly. About 14,000 patients with documented statin intolerance were randomized to bempedoic acid or placebo. The drug reduced LDL by 21% and more importantly, it reduced the primary composite of cardiovascular death, heart attack, stroke, and coronary revascularization by 13%. Heart attack specifically dropped 23%. Real cardiovascular outcomes, not just lipid numbers. So, the catch is of course, cost. It is unfortunately not yet on patent. So, Nexletol, as it's known by its brand name, runs about $300 to $450 a month if your insurance doesn't cover it. There's also a combo pill with ezetimibe called Nexlizet at similar pricing. Insurance coverage has improved, but typically requires documentation of statin intolerance and a prior authorization. This is genuinely for statin intolerant patient who needs additional LDL lowering beyond what ezetimibe alone provides. You can use it with or without ezetimibe. I recommend with and you can even use it with a very low dose statin if you can tolerate a small amount. Double it up and of course, it's not usually a first line drug just given all of the caveats. But for the right patient, it really fills a gap.
Before I move to the newer agents, I want to put in a brief note about two older drug classes that complete the picture because I want you to know the context. You're going to hear about these drugs if you look online or maybe even some of your doctors still talk about these. And I this to be a comprehensive episode for everyone. Bile acid sequestrants, these are colesevelam, cholestyramine. These drugs work really great in your gut. They bind bile acids in the intestine preventing their reabsorption. Your liver then needs to make more bile acids from cholesterol which lowers the circulating cholesterol. LDL reductions of about 15 to 30% have been shown and these drugs have been around since the 1960s. So, we've got tons of data. Cholestyramine was one of the first drugs ever shown to reduce cardio vascular events back in the Lipid Research Clinics Trial in 1984. Why don't we use them very much today? GI side effects. You get bloating, constipation and the pills are really large, often requiring mixing with liquid. Cholestyramine in particular is notoriously unpleasant to take. Colesevelam is a bit more tolerable and unfortunately, they can interfere with absorption of other medications. They're not first-line anymore, but for patients who genuinely cannot tolerate anything else or for mild LDL elevation in someone who refuses or cannot take all the other options, they remain available and are pretty cheap.
Now, let's talk fibrates. Fenofibrate, gemfibrozil, the primary indication is triglyceride reduction where they can lower triglycerides by 30 to 50%. The LDL effect is pretty modest and variable, so we don't really use it for that and the cardiovascular outcomes data is pretty inconsistent. So, they're not really recommended as primary LDL lowering agents for ASCVD prevention. But, for patients with very high triglycerides above 500 mg per deciliter where pancreatic risk is real at that level, fibrates have a role and fenofibrate is sometimes added in diabetic patients to address the combination of high triglyceride and low HDL. Neither of these classes is part of my typical go-to toolkit for ASCVD prevention in 2026, but a comprehensive lipid episode really requires acknowledging all of the options because you never know, you might be part of the rare few that needs some of these extra options.
There's one more drug in the foundational toolkit that I haven't covered yet, and it belongs in a different category. It's not primarily for LDL. It's for triglycerides and residual cardiovascular risk. Icosapent ethyl, brand name Vascepa, this is highly purified EPA. So, you might recognize EPA because that's one of the omega-3 fatty acids that we care about. It's the type that we primarily use for heart disease prevention. Except, it's given at a prescription dose of 4 g per day. That's not your typical fish oil capsule from the supplement aisle. The purity matters enormously here. So, the REDUCE-IT trial enrolled 8,000 plus patients with either established cardiovascular disease or diabetes, all on stable statin therapy, and all with elevated triglycerides between 135 and 499 mg per deciliter. So, half of them got Vascepa, half of them got placebo, and over 5 years, Vascepa delivered a 25% relative risk reduction in the primary cardiovascular endpoint. So, that's counting all kinds of cardiovascular death, heart attack,
The REDUCE-IT trial demonstrated significant cardiovascular benefits with icosapent ethyl (Vascepa), counting all cardiovascular death, heart attack, stroke, unstable angina, and coronary revascularization events including stent placement. The number needed to treat was 21, representing a meaningful effect size. The mechanism extends beyond triglyceride lowering, as pure EPA exhibits anti-inflammatory effects on arterial walls, anti-thrombotic properties, and plaque-stabilizing effects. Pure EPA does not raise LDL, which is critical because combined EPA plus DHA omega-3 supplements can raise LDL in some patients.
Vascepa is pure EPA only, while over-the-counter fish oil typically contains a mix of EPA and DHA at lower doses. The STRENGTH trial using a mixed formulation did not achieve the same positive results. This medication is FDA-approved specifically for people with established cardiovascular disease or diabetes with elevated triglycerides despite being on a statin. Patients with triglycerides above 150 who are already on a statin should ask their doctor specifically about Vascepa.
PCSK9 inhibitors represent the heavy artillery for patients when statins plus ezetimibe aren't enough, or when familial hypercholesterolemia exists, or when a cardiac event has occurred with apoB still above target. These monoclonal antibodies include evolocumab (Repatha) and alirocumab (Praluent), injected every 2 weeks or once a month.
The liver has LDL receptors that grab LDL particles from blood for disposal, with receptors recycled back to the surface. PCSK9 tags these receptors for destruction, reducing their numbers. Blocking PCSK9 keeps the full complement of receptors active, causing LDL to plummet. On top of a statin, PCSK9 inhibitors reduce LDL another 50 to 65%.
The FOURIER trial with 27,500 patients who had cardiovascular disease already on statins showed evolocumab dropped LDL by 59% and reduced the primary cardiovascular endpoint by 15%. The ODYSSEY Outcomes trial with 19,000 patients who had already had a heart attack showed alirocumab reduced LDL by 55% with a 15% reduction in cardiovascular events.
When PCSK9 inhibitors first launched, they cost over $14,000 a year with extraordinarily high prior authorization rejection rates. The list price has since dropped to approximately $5,850 per year. Prior authorization is still required, typically needing documentation of established cardiovascular disease or familial hypercholesterolemia and evidence that maximally tolerated oral therapy isn't meeting target.
Manufacturers offer patient assistance programs including co-pay cards from Amgen (Repatha) and Sanofi Regeneron (Praluent) that can reduce out-of-pocket cost to as low as $25 per month for commercially insured patients. Foundation-based free drug programs exist for uninsured or underinsured patients. The obstacle around these drugs should not be paperwork.
ApoE4 carriers (20 to 25% of the population) show about 10% less LDL-C reduction from statins. For ApoE4 carriers whose statin isn't performing as expected, this might be part of the reason and supports escalating to injectable therapy rather than titrating up statin dose. The speaker is ApoE3 E3 (most common genotype, about 65% of population) with no ApoE4, and does not have the protective ApoE2 genotype.
The speaker takes Repatha, letting it warm at room temperature for half an hour before injection. After a couple years of treatment, a CTCA with AI screening showed zero plaque, zero soft plaques, and zero calcified plaque, which was very unusual given family history and starting numbers.
The speaker had a carotid intima-media thickness (CIMT) test that indicated statin necessity, though the theory is there was probably just a little plaque in the carotid that the experienced technician detected. The theory is that catching atherosclerosis early enough can reverse some of its progress. A lipidologist mentioned that the margin of error on CIMT is roughly as wide as a carotid artery wall, meaning normal tests can be abnormal and abnormal tests can be normal.
About 1 in 300,000 people have homozygous familial hypercholesterolemia (HoFH), where both copies of the LDL receptor gene are broken and the liver has essentially no functional LDL receptors. PCSK9 inhibitors and statins are nearly useless for these patients since they work through LDL receptor pathways.
Three options work for HoFH patients. Evinacumab (Evkeeza) is a monoclonal antibody targeting ANGPTL3, reducing LDL by about 47% even in patients with null LDL receptor mutations through an LDL receptor-independent pathway. It requires IV infusion every 4 weeks.
Lomitapide (Juxtapid) blocks VLDL particle assembly in liver cells, reducing LDL by 40 to 50%. Significant GI side effects, liver fat accumulation, and hepatotoxicity risk require a REMS program and strict dietary fat restriction (less than 20% of calories from fat).
LDL apheresis mechanically filters LDL and Lp(a) particles from blood, acutely reducing LDL by 70 to 80% per session. It requires weekly or biweekly repetition and is available only at specialized centers.
Inclisiran dropped LDL-C 64.6% in 8 weeks when added to a statin, beating guideline-recommended oral non-statin therapies including ezetimibe and bempedoic acid. By week 24, the reduction was 62.9%, and by 52 weeks it was 58%. Nearly 90% of patients remained on the drug after one year.
Inclisiran uses small interfering RNA (siRNA) technology to silence the PCSK9 gene inside liver cells before the protein is produced. It reduces LDL by about 50 to 52% consistently across 18 months of follow-up. The convenience advantage is that only two injections per year are required instead of 26 with PCSK9 antibodies, though they must be administered in a clinic.
The VICTORION-2P cardiovascular outcomes trial is fully enrolled with results expected late 2025 or 2027. List price is $6,500 to $8,500 per year, billed under the medical benefit rather than pharmacy benefit.
Lp(a) is 90 to 95% genetically determined, with 20 to 25% of the global population having elevated levels that increase cardiovascular risk. Current drugs targeting LDL particles don't meaningfully lower Lp(a), though PCSK9 inhibitors reduce it by 20 to 30% as a secondary effect. Statins may paradoxically raise Lp(a) by 10 to 20% in some people.
The Lp(a) drug pipeline includes pelacarsen (antisense oligonucleotide) showing approximately 80% Lp(a) reduction in phase 2, with the Lp(a) HORIZON outcomes trial enrolling over 8,000 patients. Olpasiran (siRNA targeting LPA gene) showed greater than 95% Lp(a) reduction at higher doses in phase 2. Mipomersen (oral small molecule) showed up to 65% Lp(a) reduction. Ziltaciran showed greater than 90% Lp(a) reduction lasting nearly a year after a single dose. Lepadisiran showed approximately 94% Lp(a) reduction at highest dose with effects lasting more than 12 months.
The ACCLAIM-Lp(a) trial is the first phase 3 Lp(a) outcomes trial to include primary prevention patients. Outcomes data expected between 2026 and 2028 across multiple agents.
Obicetrapib is a next-generation CETP inhibitor showing LDL reductions of 42 to 45% on top of statin therapy and lowering Lp(a) by 35 to 50%. The PREVAIL outcomes trial with over 9,000 patients has results expected in late 2026. CETP inhibitors had a disastrous history with earlier drugs failing or causing harm, but obicetrapib has different chemistry and no off-target effects.
Colchicine at 0.5 mg once daily has shown meaningful reduction in major cardiovascular events in patients with coronary artery disease through two large randomized controlled trials. Atherosclerosis involves both cholesterol storage and inflammatory processes, with residual inflammation driving residual risk even with optimal LDL control.
The LoDoCo 2 trial enrolled 5,500 patients with stable coronary artery disease, showing 31% relative risk reduction in the primary cardiovascular composite. The COLCOT trial showed similar results in post-MI patients. A 2025 secondary analysis showed consistent benefit in both high-risk and lower-risk subgroups.
Caveats include a signal for slightly higher non-cardiovascular death in some analyses and potential bone marrow effects. GI side effects affect about 10% of patients. For patients with established coronary heart disease who have optimal apoB but persistently high hs-CRP, colchicine 0.5 mg daily can be part of the treatment toolkit.
Abelacimab is a monoclonal antibody blocking factor XI, a protein in the clotting cascade. Factor XI is critical for pathological thrombus formation causing heart attacks and strokes, but less important for normal bleeding prevention. Blocking factor XI provides anticoagulation with reduced bleeding risk compared to current anticoagulants like Coumadin.
Abelacimab is a monoclonal antibody targeting Factor XI that is being evaluated as an anticoagulant. The AZALEA-TIMI 71 trial, published in NEJM in 2025, compared abelacimab directly to rivaroxaban in patients with atrial fibrillation and moderate to high stroke risk. Results showed dramatically lower bleeding rates with abelacimab compared to rivaroxaban, though stroke efficacy is still being evaluated in larger trials. The AZALEA-TIMI 71 trial was primarily powered for bleeding, with larger outcome trials ongoing.
This matters for lipid management because patients who need aggressive lipid lowering—including those with established atherosclerotic cardiovascular disease, familial hypercholesterolemia, or high Lp(a)—often have atrial fibrillation or need anticoagulation for other reasons. The intersection of cardiovascular risk reduction and anticoagulation safety represents a potential practice-changing opportunity for abelacimab. Phase three outcomes trials are ongoing, with potential approval in 2027 or 2028.
Verve 101 from Verve Therapeutics represents a gene therapy approach using base editing to permanently turn off the PCSK9 gene. A single infusion changes one chemical letter (A to G) in the PCSK9 gene, introducing a stop signal that permanently inactivates the gene without double-stranded breaks. The Heart One trial demonstrated approximately 55% LDL reduction. Two patients in higher dose groups experienced cardiovascular events shortly after infusion, but investigators attributed these to underlying severe disease rather than the therapy. The FDA has placed a clinical hold on US trials pending additional safety review. Verve is developing Verve 102 with a different delivery system.
Timeline estimates place first approved gene editing therapy for common lipid disorders in the early 2030s. For patients with familial hypercholesterolemia requiring lifetime injections or plasma pheresis every few weeks, this represents a potential single-infusion permanent solution.
Dietary changes can reduce apoB by 10 to 20% through reducing saturated fat and replacing with unsaturated fats from nuts, seeds, and olive oil. Adding soluble fiber from oats, barley, and legumes can push reductions to 20 to 30% in highly adherent individuals. The Portfolio diet combines these approaches and has shown LDL reductions approaching low-intensity statin levels. However, for anyone with apoB above 100, plaque on imaging, or family history of cardiovascular disease, diet alone is insufficient.
Plant sterols may lower LDL but are atherogenic, introducing a different harmful lipid into the body. Exercise provides minimal direct effect on apoB and LDL (approximately 5 to 10% reduction) but benefits cardiovascular health through triglyceride reduction and HDL improvement. VO2 max remains one of the strongest predictors of all-cause mortality.
Weight loss of 10 kg (22 lb) produces approximately 8 to 10-point LDL drops with meaningful improvements in triglycerides and insulin sensitivity. Lifestyle remains foundational and non-negotiable for longevity but does not replace medication for most people with genuinely elevated cardiovascular risk. For Lp(a), diet, exercise, and weight loss have zero effect.
Tier 1 (Moderate Risk): Elevated apoB with family history but no established cardiovascular disease or confirmed FH. Start with high-intensity statin (rosuvastatin 20-40 mg or atorvastatin 40-80 mg). Recheck apoB in 8 to 12 weeks. Add ezetimibe 10 mg if not at goal, recheck again in 8 to 12 weeks. This combination costs under $30 monthly.
Tier 1B (Elevated Lp(a)): Same approach but set lower apoB goals to compensate for additive risk from Lp(a). Watch for upcoming Lp(a)-specific drugs.
Tier 2 (High Risk): Confirmed FH, prior cardiovascular events, significant plaque on imaging, or not at goal on maximally tolerated oral therapy. PCSK9 inhibitors or inclisiran should be first-line rather than last resort for this group.
Tier 3 (Statin Intolerant): Documented genuine intolerance with proper rechallenge. Use bempedoic acid plus ezetimibe as base therapy. Add PCSK9 inhibitor or inclisiran if needed. Excellent lipid control remains achievable without statin tolerance.
ApoB is the treatment target, not LDL-C. Goals: below 80 for primary prevention, below 70 for high-risk, below 55 for very high-risk including those with prior cardiovascular events. Recheck apoB 8 to 12 weeks after starting or changing therapy, then every 6 to 12 months once at goal. Routine liver and muscle enzyme monitoring is no longer recommended without symptoms.
Key questions to ask healthcare providers:
- What is my apoB? (Request testing if only LDL-C has been measured)
- Has my Lp(a) ever been tested? (One-time test that doesn't change over lifetime)
- Given my family history, am I being treated aggressively enough? (Early cardiovascular disease in first-degree relatives before age 55 in men or 65 in women is a strong risk factor)
- If statins aren't getting me to goal, what's next? (Ask specifically about ezetimibe, PCSK9 inhibitors, or inclisiran)
- What does cardiovascular imaging show? (CCTA or coronary calcium score findings should drive treatment targets)
A good physician welcomes these questions. Request dedicated follow-up if time is limited during visits.
Current tools include statins costing $4 monthly with evidence from over 170,000 trial participants, ezetimibe costing $5-15 monthly with 20% additional reduction and virtually no side effects, and injectable drugs achieving apoB below 50 with twice-yearly dosing options eliminating daily adherence burden. The barrier to optimal care is typically knowledge of available options and how to request them rather than access to science or evidence.
Keep Hillary Lin, MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
